Moreover, the 36-month beta value for ARQT is 1.12. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ARQT is 104.94M and currently, short sellers hold a 14.29% of that float. On April 09, 2024, ARQT’s average trading volume was 4.73M shares.
ARQT) stock’s latest price update
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)’s stock price has increased by 10.49 compared to its previous closing price of 11.34. However, the company has seen a 29.44% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-28 that Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
ARQT’s Market Performance
ARQT’s stock has risen by 29.44% in the past week, with a monthly rise of 20.71% and a quarterly rise of 237.74%. The volatility ratio for the week is 9.07% while the volatility levels for the last 30 days are 9.01% for Arcutis Biotherapeutics Inc The simple moving average for the past 20 days is 23.16% for ARQT’s stock, with a 95.13% simple moving average for the past 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with Mizuho repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to Mizuho is $8 based on the research report published on January 03, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $4, previously predicting the price at $57. The rating they have provided for ARQT stocks is “Neutral” according to the report published on October 26th, 2023.
Goldman gave a rating of “Neutral” to ARQT, setting the target price at $6 in the report published on October 13th of the previous year.
ARQT Trading at 40.54% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.64% of loss for the given period.
Volatility was left at 9.01%, however, over the last 30 days, the volatility rate increased by 9.07%, as shares surge +12.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +158.88% upper at present.
During the last 5 trading sessions, ARQT rose by +29.44%, which changed the moving average for the period of 200-days by +29.71% in comparison to the 20-day moving average, which settled at $10.24. In addition, Arcutis Biotherapeutics Inc saw 287.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Heron Patrick J, who purchase 21,052 shares at the price of $9.50 back on Mar 04 ’24. After this action, Heron Patrick J now owns 8,785,284 shares of Arcutis Biotherapeutics Inc, valued at $199,994 using the latest closing price.
Watanabe Todd Franklin, the of Arcutis Biotherapeutics Inc, sale 14,903 shares at $11.12 during a trade that took place back on Mar 04 ’24, which means that Watanabe Todd Franklin is holding 874,533 shares at $165,739 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -4.04 for the present operating margin
- 0.91 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -4.39. The total capital return value is set at -0.82.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -1.22. The debt to equity ratio resting at 2.28. The interest coverage ratio of the stock is -8.11.
Currently, EBITDA for the company is -239.22 million with net debt to EBITDA at -0.5. When we switch over and look at the enterprise to sales, we see a ratio of 26.12. The receivables turnover for the company is 2.31for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.08.
Conclusion
To wrap up, the performance of Arcutis Biotherapeutics Inc (ARQT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
